- The trend backdrop is active with a 36-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
IOVA
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Iovance Biotherapeutics Inc · Healthcare · Biotechnology
Latest close
4.99 USD
-0.2%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 37.7% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned -0.2%, after a 17.4% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers. Options positioning is bullish with 59/100 conviction, while the latest news-sentiment score is 56/100. Near-term considerations: earnings are due in 8d.
Setup score
72
out of 100
Latest Close
4.99 USD
24 Jul 2026
1W Return
-0.2%
latest completed week
4W Return
17.4%
short-term follow-through
12W Return
46.8%
quarterly tape
Trend Breadth
69.2%
36 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.2%
Latest completed week; four-week move 17.4%.
Indicator stack
83/100
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Bullish
59/100 conviction; expected move 7.0%.
News sentiment
56/100
59 relevant articles in the latest sentiment read.
Event risk
8d
Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 37.7% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned -0.2%, after a 17.4% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.7512-week average 0.64
12-week confirmation
Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure8/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.75Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 17.4% over four weeks, 46.8% over 12 weeks, and 59.4% over one year. The current trend has remained active for 36 consecutive weeks.
Performance by holding period
Active trend streak36 weeks
Active weeks in one year36
Trend breadth69.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.99Latest activity-pressure read.
Pressure change5291.9%Four-week change in activity pressure.
Leadership50.31Latest relative-leadership reading.
RS change72.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks strongly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength17/100Blend of value, momentum, and quality. Underlying universe rank 84; rank 1 is best.
Value20/100Relative valuation strength. Underlying universe rank 81; rank 1 is best.
Quality10/100Profitability and accounting quality. Underlying universe rank 91; rank 1 is best.
Momentum86/100Medium-term price momentum. Underlying universe rank 15; rank 1 is best.
Growth84/100Revenue and earnings growth. Underlying universe rank 17; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 7.8x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -11.4% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 114.5% Gross profit retained from each unit of revenue.
- Operating margin
- -124.2% Operating profit retained from revenue.
- Free-cash-flow margin
- -82.8% Free cash flow generated from revenue.
- Return on invested capital
- -46.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 34.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -11.5% Net share repurchases relative to market value.
- Shareholder yield
- -11.5% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningBullish
IOVA shows bullish options pressure with a 59/100 conviction score, put-call volume ratio of 0.28, expected move of 7.0%, and Sharemaestro trend signal active.
Conviction59/100
Expected move7.0%
Put/call volume0.28
Insider activity9 / 11
9 acquisitions and 11 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment56/100
Weighted news tone is neutral across 59 relevant articles.
22 positive · 32 neutral · 5 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings8dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move7.0%Nearest-chain priced movement where available.
52-week drawdown-11.5%Distance below the 52-week high.
13-week volatility7.6%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher12 of 2614 weeks finished lower.
Best week+34.5%Week of 27 Feb.
Worst week-22.8%Week of 13 Mar.
Latest week-0.2%Week of 24 Jul.
Shape of recent returns
Strong gains9
Modest gains3
Flat weeks0
Modest losses8
Sharp losses6
Recent vol7.6%13-week weekly-return volatility.
Base vol12.0%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew11.3% / -7.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank5 / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape71/100
Trend, activity pressure, participation, and risk combine to a 71/100 tape read.
Indicator analysis80/100Latest 12-week confirmation: trend 12/12, activity pressure 8/12, relative leadership 12/12.
Activity pressure 0.75; No reversal markers Factors30/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 87; Small Cap Core rank 84 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options68/100IOVA shows bullish options pressure with a 59/100 conviction score, put-call volume ratio of 0.28, expected move of 7.0%, and Sharemaestro trend signal active.
Bullish · Call-side pressure · Expected move 7.0% Sentiment56/100Weighted news tone is neutral across 59 relevant articles.
Iovance Biotherapeutics Inc (IOVA) Institutional Confidence Insiders9 / 119 acquisitions and 11 disposals in the latest 180-day insider tape.
Earnings8dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 4.99 USD | -0.2% | 3.62 USD | 5.92 USD | 0.99 | 50.31 | 70.0M | On |
| 17 Jul 2026 | 5.00 USD | 18.2% | 3.55 USD | 5.93 USD | 0.83 | 49.24 | 122.1M | On |
| 10 Jul 2026 | 4.23 USD | -1.9% | 3.47 USD | 5.95 USD | 0.39 | 22.57 | 58.4M | On |
| 3 Jul 2026 | 4.31 USD | 1.4% | 3.40 USD | 5.97 USD | 0.16 | 28.42 | 62.9M | On |
| 26 Jun 2026 | 4.25 USD | 8.7% | 3.33 USD | 5.99 USD | -0.02 | 29.25 | 77.9M | On |
| 19 Jun 2026 | 3.91 USD | -4.2% | 3.27 USD | 6.01 USD | -0.22 | 14.95 | 56.6M | On |
| 12 Jun 2026 | 4.08 USD | -3.5% | 3.22 USD | 6.03 USD | -0.13 | 23.93 | 53.9M | On |
| 5 Jun 2026 | 4.23 USD | 3.2% | 3.16 USD | 6.06 USD | -0.09 | 32.23 | 79.1M | On |
| 29 May 2026 | 4.10 USD | -0.2% | 3.10 USD | 6.08 USD | 0.00 | 23.50 | 53.9M | On |
| 22 May 2026 | 4.11 USD | 19.1% | 3.03 USD | 6.11 USD | 0.01 | 28.58 | 61.4M | On |
| 15 May 2026 | 3.45 USD | -4.7% | 2.97 USD | 6.14 USD | 0.07 | 10.30 | 68.4M | On |
| 8 May 2026 | 3.62 USD | 6.5% | 2.92 USD | 6.16 USD | 0.33 | 16.21 | 119.7M | On |
| 1 May 2026 | 3.40 USD | -1.2% | 2.87 USD | 6.19 USD | 0.51 | 15.91 | 56.8M | On |
| 24 Apr 2026 | 3.44 USD | -10.9% | 2.84 USD | 6.21 USD | 0.64 | 17.97 | 69.9M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.